Significant advancements in lung cancer treatment were seen throughout 2024, from new drug approvals to promising clinical ...

Akriti Jain, MD, discusses her presentation from the 2024 American Society of Hematology Meeting and Exposition.

Saeed Sadeghi, MD, discusses valuable feedback he heard from oncologists on the use of luspatercept-aamt in patients with low-risk myelodysplastic syndrome.

Alfa, MD, discusses the findings and key takeaways from the SUMMIT trial, which evaluated the use of neratinib for the ...

During a Case-Based Roundtable® event, Daniel J. George, MD, discusses how often community oncology participants see patients ...

Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

A panelist discusses how infusion-related reactions to monoclonal antibodies in EGFR-mutated NSCLC can be effectively managed ...

A panelist discusses how molecular testing for patients with MBC who relapse during or shortly after adjuvant endocrine ...

A new drug application seeking the accelerated approval of dordaviprone forrecurrent for H3K27M-mutant diffuse glioma ...

Sacituzumab govitecan, currently indicated in triple-negative breast cancer (TNBC), is undergoing evaluation in NSCLC. In ...

Pancreatic ductal adenocarcinoma remains a challenge to treat due to its complex biology and resistance mechanisms.